Why Genfit Shares Are Rising
Genfit SA (NASDAQ: GNFT) shares are trading higher after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor.
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
Here's a roundup of top developments in the biotech space over the last 24 hours.
20 Stocks Moving in Friday’s Pre-Market Session
Gainers
Genfit SA (NASDAQ: GNFT) rose 47.5% to $4.90 in pre-market trading. Ipsen and GENFIT reported an exclusive licensing agreement for Elafibranor.
Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
Ipsen SA (OTC: IPSEY) has
Ipsen and GENFIT Announced Exclusive Licensing Agreement for Elafibranor; GENFIT Receives €120M Upfront, Up to €360M in Milestone Payments Plus Royalties of up to 20%; Ipsen Becomes 8% Shareholder of GENFIT
Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq: GNFT) have entered into a long-term strategic partnership for global collaboration between the two companies.
HC Wainwright & Co. Maintains Neutral on Genfit, Lowers Price Target to $7
HC Wainwright & Co. analyst Ed Arce maintains Genfit (NASDAQ:GNFT) with a Neutral and lowers the price target from $8 to $7.
Earnings Scheduled For September 29, 2021
Companies Reporting Before The Bell
• AGM Gr Hldgs (NASDAQ:AGMH) is estimated to report earnings for its first quarter.
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 19)
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen’s Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 15)